Pixium Vision (PXMVF) Stock Price, News & Analysis

Company Overview

Pixium Vision SA, headquartered in Paris, France, is a clinical-stage bioelectronics company dedicated to developing innovative vision restoration systems for individuals affected by complex retinal diseases. The company’s core technology translates visual scenes captured by smart glasses into targeted electrical stimulation of the retina, aiming to restore functional vision for patients suffering from conditions such as retinitis pigmentosa and age-related macular degeneration.

Pixium Vision’s lead program, the Prima System, features a wireless photovoltaic subretinal implant paired with augmented-reality glasses that capture and process images before transmitting them to the implant. In parallel, the company has advanced its IRIS (Intelligent Retinal Implant System) series, which employs an epiretinal implant coupled with an external video processor and electrode array to stimulate retinal neurons and evoke visual perception.

Since its founding in 2011, Pixium Vision has progressed through feasibility and pivotal clinical trials across Europe, achieving CE Mark approval for select device components. The company has established research collaborations with leading academic and clinical institutions to refine implant performance and optimize patient outcomes. Regulatory submissions are underway to initiate clinical studies in North America, reflecting Pixium Vision’s commitment to global commercialization.

Governed by a board of directors and supported by an experienced leadership team, Pixium Vision continues to expand its intellectual property portfolio and manufacturing capabilities. The company remains focused on advancing its bionic vision technologies through clinical development and regulatory milestones to bring life-changing solutions to patients worldwide.

Key Stats

• Today's Range: C$0.03 to C$1.50
• 50-Day Range: C$0.03 to C$0.03
• 52-Week Range: C$0.03 to C$0.03
• Volume: N/A
• Average Volume: 8,800 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXMVF Stock Analysis - Frequently Asked Questions

How have PXMVF shares performed this year?

Pixium Vision's stock was trading at C$75.00 on January 1st, 2026. Since then, PXMVF shares have decreased by 100.0% and is now trading at C$0.03.

When did Pixium Vision's stock split?

Pixium Vision's stock reverse split on Thursday, September 21st 2023.The 1-50 reverse split was announced on Thursday, September 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Pixium Vision?

Shares of PXMVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PXMVF
• CIK: N/A
• Web: www.pixium-vision.com
• Phone: 33 1 76 21 47 68
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A